Seagen's ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
Seagen's ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
在針對早期經典霍奇金淋巴瘤患者的2期試驗中，Seagen的ADCETRIS Plus新型免疫療法組合可在12個月內實現100％的無進展存活率
– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months –
— 在試驗的晚期經典霍奇金淋巴瘤患者中，有 88% 在24個月時仍無進展 —
– Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and bleomycin, continues to show consistent safety and tolerability profile, with no cases of febrile neutropenia and no new safety signals observed –
— 消除兩種常用化療藥物（長春鹼和博來黴素）的研究方案繼續顯示出一致的安全性和耐受性，沒有出現發熱性中性粒細胞減少症病例，也沒有觀察到新的安全信號 —